权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Epigenetic Biomarker Discovery in HPV related HNSCC

HPV 相关 HNSCC 中表观遗传生物标志物的发现

基本信息

批准号：
8479498
负责人：
Joseph A Califano
金额：
$ 38.48万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-04-01 至 2018-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8479498
关键词：
Affect Age Area Biological Assay Biological Markers Blood Body Fluids Cancer Control Cervix carcinoma Characteristics Clinical DNA DNA Methylation Data Detection Development Diagnostic Diagnostic Neoplasm Staging Disease Epidemiology Epigenetic Process Gender Genetic Genome Genomics HPV-High Risk Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Human Papillomavirus Incidence Malignant Neoplasms Measurement Methods Methylation Microscopic Modality Pap smear Pathologic Patients Performance Plasma Population Premalignant Recurrence Resolution Risk Saliva Salivary Sampling Secondary Prevention Smoking Staging Techniques Testing United States Validation alcohol exposure base bisulfite case control cost effective design epigenetic marker malignant mouth neoplasm malignant oropharynx neoplasm multiplex detection novel novel strategies oral premalignancy performance tests population based pre-clinical prognostic public health relevance response screening tobacco exposure treatment response viral DNA

项目摘要

DESCRIPTION (provided by applicant): High risk human papilloma virus related head and neck squamous cell carcinoma (HPVHNSCC) incidence is rapidly increasing, and will soon surpass the incidence of cervical carcinoma in the US. There are no effective ways to detect preclinical or early HPVHNSCC, screen populations at increased risk for HPVHNSCC development, or even assay for microscopic persistence of HPVHNSCC after therapy. However, epigenetic alterations have been detected in body fluids from premalignant and early stage cancers and multiplex tests have shown promise for identification of patients with oral premalignancy. Our primary hypothesis is that multiplex testing of plasma and salivary rinses based on HPVHNSCC specific epigenetic alterations combined with high risk HPV DNA presence has potential as useful test for presence of HPVHNSCC. This project will serve as a discovery and diagnostic validation biomarker development trial for HPVHNSCC detection with potential application for assessment of disease response and development of a population based screening test.

描述（由申请人提供）：高危人乳头状瘤病毒相关头颈部鳞状细胞癌（HPVHNSCC）的发病率正在迅速增加，在美国将很快超过宫颈癌的发病率。目前还没有有效的方法来检测临床前或早期HPVHNSCC，筛查HPVHNSCC发展风险增加的人群，甚至检测治疗后HPVHNSCC的显微持久性。然而，表观遗传学改变已被检测到的体液从癌前和早期阶段的癌症和多重测试已显示出的承诺，为确定患者的口腔癌前病变。我们的主要假设是，基于HPVHNSCC特异性表观遗传学改变结合高危HPV DNA存在的血浆和唾液冲洗液的多重检测有可能作为HPVHNSCC存在的有用检测。该项目将作为HPVHNSCC检测的发现和诊断验证生物标志物开发试验，具有评估疾病反应和开发基于人群的筛查试验的潜在应用。